证券代码：002901 证券简称：大博医疗 公告编号：2026-011 大博医疗科技股份有限公司 关于 2026 年度继续使用部分闲置自有资金 进行委托理财的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、受托方：包括但不限于商业银行、信托公司、资产管理公司、证券公司、 基金公司、保险公司等具有合法经营资格的金融机构。 2、投资种类：流动性好、中高风险及以下的理财产品或存款类产品，包括 但不限于证券、银行及其理财子公司的产品、资产管理计划、债券、基金等理财 产品。 3、委托理财金额：公司及子公司拟使用不超过人民币20.00亿元（其中，中 风险及中高风险产品投资额度合计不超过人民币4.00亿元）的自有资金进行委托 理财。在该额度范围内，资金可循环滚动使用，期限内任一时点投资金额不得超 出上述投资额度。 4、额度使用期限：自股东会审议通过之日起 12 个月内有效。 5、履行的审议程序：大博医疗科技股份有限公司（以下简称"公司"）于 2026 年 3 月 23 日召开了第四届董事会第二次会议，审议通过了《关于 2026 年 度继续使用部分闲 ...

证券代码：002901 证券简称：大博医疗 公告编号：2026-013 大博医疗科技股份有限公司 为满足公司及子公司生产经营及业务拓展的需要，公司及控股子公司拟向有 关金融机构申请不超过 180,000 万元人民币的综合授信额度。额度有效期为自 本议案经股东会审议通过之日起一年。具体如下： | 银行名称 | 授信额度 | | --- | --- | | 中国农业银行股份有限公司厦门分行 | 不超过 亿 1.5 | | 招商银行股份有限公司厦门分行 | 不超过 亿 3.0 | | 中国工商银行股份有限公司厦门分行 | 不超过 亿 1.5 | | 中信银行股份有限公司厦门分行 | 不超过 1.5 亿 | | 兴业银行股份有限公司厦门分行 | 不超过 亿 4.5 | | 厦门银行股份有限公司 | 不超过 亿 1.0 | | 中国建设银行股份有限公司厦门分行 | 不超过 亿 2.0 | | 中国光大银行股份有限公司厦门分行 | 不超过 1.0 亿 | | 中国银行股份有限公司厦门分行 | 不超过 亿 1.0 | | 中国民生银行股份有限公司厦门分行 | 不超过 亿 1.0 | 上述授信额度不等于公司的实际融资金额，实 ...

证券代码：002901 证券简称：大博医疗 公告编号：2026-012 大博医疗科技股份有限公司 关于开展 2026 年度外汇衍生品交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 2026年3月23日，大博医疗科技股份有限公司（以下称"公司"）召开第四 届董事会第二次会议，审议通过了《关于开展2026年度外汇衍生品交易的议案》， 同意公司开展外汇衍生品业务，交易规模在任意时点余额不超过3,000万美元， 交易金额在上述额度范围内可滚动实施，实施期限自公司股东会审议通过之日起 12个月内。本议案尚需提交公司股东会审议。具体情况如下： 一、开展外汇衍生品交易的目的 由于公司部分产品存在境外销售，随着公司在境外市场的不断拓展，外币结 算业务量也逐步增加，因此当汇率出现较大波动时，汇兑损益对公司的经营业绩 会造成一定影响。为了降低汇率波动对公司利润的影响，公司计划开展外汇衍生 品交易。 二、外汇衍生品交易业务概述 1、合约期限：不超过一年； 2、合约金额：不超过 3,000 万美元； 3、交易对手：银行类金融机构； 4、交易品种：金融机构提供的外汇远期、结 ...

大博医疗科技股份有限公司 关于开展外汇衍生品交易业务的可行性分析报告 一、公司开展外汇衍生品交易的背景 随着大博医疗科技股份有限公司（以下简称"公司"）在境外市场的不断拓 展，外币结算业务量也逐步增加，为有效规避外汇市场风险，减少汇兑损益对公 司经营业绩造成的影响，公司计划开展外汇衍生品交易，满足公司稳健经营的需 求。 二、公司开展的外汇衍生品交易业务概述 1、合约期限：不超过一年； 2、合约金额：不超过 3,000 万美元； 3、交易对手：银行类金融机构； 4、交易品种：金融机构提供的外汇远期、结构性远期、外汇期权等业务； 5、流动性安排：衍生品投资以正常的外汇收支业务为背景，投资金额和投 资期限与预期收支期限相匹配； 6、业务授权：提请股东会授权公司管理层根据公司实际生产经营需求情况 在上述额度内开展相关交易，并签署上述交易项下的合同及其他有关法律文件； 7、实施期限：自公司股东会审议通过之日起 12 个月内。 三、公司开展外汇衍生品交易的必要性和可行性 公司已建立《外汇衍生品交易业务管理制度》并根据相关法律法规制定并完 善了相关内控制度，为开展外汇衍生品交易配备了专业人员，公司采取的针对性 风险控制措施 ...

证券代码：002901 证券简称：大博医疗 公告编号：2026-015 大博医疗科技股份有限公司 关于召开 2026 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2026 年第二次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所 股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公 司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》的有关 规定。 4、会议时间： （1）现场会议时间：2026 年 4 月 8 日（星期三）14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026 年 4 月 8 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联 网投票系统投票的具体时间为 2026 年 4 月 8 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2026 年 4 ...

证券代码：002901 证券简称：大博医疗 公告编号：2026-014 大博医疗科技股份有限公司 第四届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 大博医疗科技股份有限公司（以下简称"公司"）第四届董事会第二次会议 于 2026 年 3 月 23 日在公司会议室以现场及通讯相结合方式召开，会议通知以专 人送达、传真、电子邮件、电话相结合的方式已于 2026 年 3 月 16 日向各位董事 发出，本次会议应参加董事 7 名，实际参加董事 7 名，本次会议的召开符合《公 司法》《公司章程》等法律法规的规定，合法有效。 具体内容详见公司于2026年3月24日刊登在指定信息披露媒体及巨潮资讯网 （www.cninfo.com.cn）上的《关于开展2026年度外汇衍生品交易的公告》。 本议案尚需提交公司 2026 年第二次临时股东会审议。 三、会议以7票赞成、0票反对、0票弃权的表决结果审议通过了《关于开展 外汇衍生品交易业务的可行性分析报告的议案》。 本次会议由董事长林志雄先生主持，与会董事就会议议案进行了审议、表决， 形成了如下决议： ...

Core Viewpoint - The orthopedic industry is facing issues of high sales expenses and shrinking R&D investment, with major companies like Dabo Medical having sales expense ratios above the industry average [1] Group 1: Company Developments - Dabo Medical has recently made a new investment, fully acquiring Maikoste (Xiamen) Medical Equipment Co., Ltd. with a registered capital of 5 million yuan, focusing on professional technical services [1] Group 2: Stock Performance - Dabo Medical's stock price decreased from 50.14 yuan to 48.03 yuan over the past week, reflecting a decline of 2.66% and a volatility of 6.49%; on February 11, the stock fell by 1.58% with a net outflow of 10.377 million yuan [2] - As of February 12, the stock price slightly increased by 0.36% to 48.03 yuan, with a turnover rate of 0.60% and a trading volume of 82.96 million yuan; technical indicators suggest a downward trend [2] Group 3: Financial Performance - Dabo Medical expects a net profit attributable to shareholders for the year 2025 to be between 580 million yuan and 610 million yuan, representing a year-on-year growth of 62.55% to 70.96%; the non-recurring net profit is projected to grow by 59.42% to 69.93% [3] - The primary drivers of this growth are focused on core business, product innovation, and the advancement of international strategies, with a revenue of 1.876 billion yuan in the first three quarters of 2025, marking a year-on-year increase of 22.69% [3] Group 4: Institutional Insights - Institutions predict a net profit growth rate of 50.67% for 2025, with a slowdown to 16.88% in 2026; current institutional ratings are neutral, and the fund holding ratio is low at 0.88%, indicating moderate market attention [4]

Core Viewpoint - The orthopedic industry is facing scrutiny due to commercial bribery cases, while major companies are reporting significant revenue and profit growth for 2025, highlighting a contrast between industry recovery and ongoing issues of high sales expenses and unethical practices [2][6][8]. Group 1: Bribery Cases and Industry Impact - The National Healthcare Security Administration has reported significant bribery cases in the orthopedic field, with kickback rates reaching up to 40% [2][3]. - In a case involving a hospital director, illegal kickbacks totaled 2.72 million yuan, with a supplier paying 35% of the total supply as a monthly kickback [4]. - Another case revealed a hospital official receiving 3.66 million yuan in bribes over ten years, with kickback rates between 20% and 40% for various orthopedic devices [5]. Group 2: Financial Performance of Companies - Major orthopedic companies like Spring Medical, Dabo Medical, and Kelly Tai are forecasting significant revenue and profit increases for 2025, with some companies expecting profit growth exceeding 300% [2][6][7]. - The orthopedic consumables sector saw a 17% year-on-year revenue growth in the first three quarters of 2025, with net profit increasing by 81% [6][16]. - Spring Medical anticipates a net profit of 245 to 288 million yuan for 2025, representing a year-on-year increase of 96.01% to 130.41% [6][16]. Group 3: Sales Expenses and Challenges - Despite positive financial forecasts, high sales expenses remain a significant concern, with some companies' sales expense ratios exceeding the industry average [8][18]. - For instance, Dabo Medical's sales expense ratio was approximately 26.7%, indicating elevated marketing costs within the orthopedic sector [18]. - The ongoing high sales expenses are squeezing companies' research and development budgets, with reductions in R&D spending reported by several firms [19].

Core Viewpoint - The stock of Dabo Medical (002901) has shown a recent increase in price and positive financial performance, indicating potential investment opportunities in the medical device sector. Group 1: Stock Performance - As of February 5, 2026, Dabo Medical closed at 50.14 yuan, up 1.62% with a turnover rate of 0.61% and a trading volume of 17,600 shares, resulting in a transaction value of 88.34 million yuan [1] - On February 5, 2026, the net inflow of main funds was 418,700 yuan, accounting for 0.47% of the total transaction value, while retail investors saw a net inflow of 1.17 million yuan, representing 1.33% of the total [1] Group 2: Financing and Margin Trading - On February 5, 2026, the financing buy amounted to 7.38 million yuan, while financing repayment was 9.08 million yuan, resulting in a net repayment of 1.70 million yuan [1] - The total financing balance on February 5, 2026, was 155 million yuan, with a margin trading balance of 155 million yuan [2] Group 3: Financial Metrics and Industry Comparison - Dabo Medical's total market capitalization is 20.76 billion yuan, with a net profit of 425 million yuan, which is significantly higher than the industry average of 208 million yuan [4] - The company reported a gross margin of 71.23% and a net profit margin of 23.92%, both of which are above the industry averages of 50.55% and 9.59%, respectively [4] - For the first three quarters of 2025, Dabo Medical's main revenue was 1.88 billion yuan, a year-on-year increase of 22.69%, and the net profit attributable to shareholders was 425 million yuan, up 77.03% year-on-year [4]

Core Viewpoint - Dabo Medical (002901) shows a positive trend in stock performance and financial metrics, indicating potential growth opportunities in the medical device industry. Financial Performance - As of February 3, 2026, Dabo Medical's stock closed at 49.75 yuan, up 1.12%, with a trading volume of 18,500 lots and a transaction value of 91.64 million yuan [1] - For the first three quarters of 2025, the company reported a main revenue of 1.876 billion yuan, a year-on-year increase of 22.69%, and a net profit of 425 million yuan, up 77.03% year-on-year [2] - The company's gross profit margin stands at 71.23%, significantly higher than the industry average of 50.55% [2] Market Position - Dabo Medical has a total market capitalization of 20.597 billion yuan, ranking 12th in the medical device industry [2] - The company has a price-to-earnings ratio (P/E) of 36.38, which is lower than the industry average of 97.37, indicating a potentially undervalued stock [2] - The return on equity (ROE) is 12.83%, placing the company 8th in the industry, which reflects strong profitability compared to peers [2] Recent Trading Activity - On February 3, 2026, the net outflow of main funds was 2.7838 million yuan, while retail investors saw a net inflow of 1.1964 million yuan [1] - Over the past five days, the stock has experienced fluctuations in fund flows, with notable retail interest despite some institutional selling [1]